From Big Data to Better Drugs: How AI-Driven Platforms Are Changing Cancer Research
- Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually.
- The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers.
- The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β.
- This has now expanded to >20M abstracts representing the totality of scientific literature.
Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large and complex biomedical datasets, which are often incredibly difficult and time-consuming to go through manually.
Trying to analyze the datasets manually just isn’t feasible in most cases, not only due to the amount of time and effort it would take, but also due to human error and inconsistencies. Thankfully, there are platforms that have been developed that can dramatically speed up and improve this process.
One such example is the PDAOAI platform, which was developed by Oncotelic Therapeutics Inc. (OTCQB: OTLC). PDAOAI is a proprietary evidence-interrogation platform, which is designed to analyze large biomedical datasets and extract meaningful signals from the data.
Instead of training a model to imitate your dataset, it structures, embeds, clusters, and queries large bodies of biomedical knowledge so the dataset can “speak” and yield reproducible, auditable, and testable hypotheses. This ultimately helps to reduce bias and give researchers a more interactive discovery experience.
Oncotelic also curated a comprehensive TGF-β literature corpus that contains more than 125,000 PubMed abstracts, which represents the totality of scientific knowledge related to TGF-β across areas like oncology, immunology, fibrosis, metabolism, and translational therapeutics.
This TGF-β knowledge corpus also supports collaboration between researchers, academics, and other collaborators, as the TGF-β corpus community is hosted on Discord to support discussion and exploration.
Whether in relation to cancer research or not, AI and data platforms are becoming essential in biotech in general. The industry requires the analysis, management, and interpretation of huge amounts of data, which simply cannot be handled manually without the process being incredibly slow and intensive.
Using AI and data platforms may speed up the analysis process, automate some previously-tedious research and/or experiments, and reduce costs. It may also help with identifying potential drug targets, accelerating drug discovery and development, and unify siloed data in less time and with less effort than traditional methods.
About Oncotelic Therapeutics Inc. (OTCQB: OTLC)
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company that’s developing RNA-based immunotherapy, and targeted therapeutics for cancer and other diseases. It aims to transform outcomes for patients with difficult-to-treat conditions, and the company’s strategy focuses on novel compound design, nanoparticle drug delivery, and integrating AI to speed up discovery and regulatory workflows.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
- Cancer research often relies on massive and complex datasets, which can take time and effort to sift through manually.
- The proprietary PDAOAI platform from Oncotelic Therapeutics helps with this problem as it was designed to analyze large biomedical datasets to extract meaningful signals and help researchers.
- The company has also curated a detailed TGF-β literature corpus containing 125,000+ PubMed abstracts that represents all of the scientific knowledge related to TGF-β.
- This has now expanded to >20M abstracts representing the totality of scientific literature.
Cancer research is crucial for understanding, diagnosing, treating, and preventing the disease. However, this research often relies on large and complex biomedical datasets, which are often incredibly difficult and time-consuming to go through manually.
Trying to analyze the datasets manually just isn’t feasible in most cases, not only due to the amount of time and effort it would take, but also due to human error and inconsistencies. Thankfully, there are platforms that have been developed that can dramatically speed up and improve this process.
One such example is the PDAOAI platform, which was developed by Oncotelic Therapeutics Inc. (OTCQB: OTLC). PDAOAI is a proprietary evidence-interrogation platform, which is designed to analyze large biomedical datasets and extract meaningful signals from the data.
Instead of training a model to imitate your dataset, it structures, embeds, clusters, and queries large bodies of biomedical knowledge so the dataset can “speak” and yield reproducible, auditable, and testable hypotheses. This ultimately helps to reduce bias and give researchers a more interactive discovery experience.
Oncotelic also curated a comprehensive TGF-β literature corpus that contains more than 125,000 PubMed abstracts, which represents the totality of scientific knowledge related to TGF-β across areas like oncology, immunology, fibrosis, metabolism, and translational therapeutics.
This TGF-β knowledge corpus also supports collaboration between researchers, academics, and other collaborators, as the TGF-β corpus community is hosted on Discord to support discussion and exploration.
Whether in relation to cancer research or not, AI and data platforms are becoming essential in biotech in general. The industry requires the analysis, management, and interpretation of huge amounts of data, which simply cannot be handled manually without the process being incredibly slow and intensive.
Using AI and data platforms may speed up the analysis process, automate some previously-tedious research and/or experiments, and reduce costs. It may also help with identifying potential drug targets, accelerating drug discovery and development, and unify siloed data in less time and with less effort than traditional methods.
About Oncotelic Therapeutics Inc. (OTCQB: OTLC)
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company that’s developing RNA-based immunotherapy, and targeted therapeutics for cancer and other diseases. It aims to transform outcomes for patients with difficult-to-treat conditions, and the company’s strategy focuses on novel compound design, nanoparticle drug delivery, and integrating AI to speed up discovery and regulatory workflows.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
